Literature DB >> 7797919

Incidence of venereal warts in human immunodeficiency virus-infected and uninfected women.

K D Chirgwin1, J Feldman, M Augenbraun, S Landesman, H Minkoff.   

Abstract

A cohort of human immunodeficiency virus (HIV)-infected (n = 253) and uninfected (n = 658) women was prospectively studied to assess the relationship between venereal warts and HIV status, adjusting for self-reported and biologic measures of sexual risk behavior. Participants were assessed every 6 months for venereal warts and other sexually transmitted diseases, self-reported sexual behavior, and CD4 cell counts. The incidence of venereal warts was significantly increased in HIV-infected women (8.2 vs. 0.8/100 person-years of follow-up). This difference remained after adjusting for measures of high-risk sexual behavior and was observed in women at all levels of immune function, including those with > or = 500/mm3 CD4 cells. The increased risk of venereal warts in HIV infection can occur relatively early in HIV disease and appears chiefly attributable to a higher risk of progression from subclinical to clinical human papillomavirus (HPV) disease rather than to a higher risk of HPV acquisition.

Entities:  

Mesh:

Year:  1995        PMID: 7797919     DOI: 10.1093/infdis/172.1.235

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  11 in total

Review 1.  The role of vaccines in the control of STDs: HPV vaccines.

Authors:  I H Frazer
Journal:  Genitourin Med       Date:  1996-12

2.  CD4+ cell count and HIV load as predictors of size of anal warts over time in HIV-infected women.

Authors:  Hung N Luu; E Susan Amirian; Wenyaw Chan; R Palmer Beasley; Linda B Piller; Michael E Scheurer
Journal:  J Infect Dis       Date:  2012-01-13       Impact factor: 5.226

3.  Tissue specific HPV expression and downregulation of local immune responses in condylomas from HIV seropositive individuals.

Authors:  I Arany; T Evans; S K Tyring
Journal:  Sex Transm Infect       Date:  1998-10       Impact factor: 3.519

Review 4.  [Genital warts in HIV-infected individuals].

Authors:  U Wieland; A Kreuter
Journal:  Hautarzt       Date:  2017-03       Impact factor: 0.751

5.  Analysis of CD4(+) T-cell responses to human papillomavirus (HPV) type 11 L1 in healthy adults reveals a high degree of responsiveness and cross-reactivity with other HPV types.

Authors:  O Martin Williams; Keith W Hart; Eddie C Y Wang; Colin M Gelder
Journal:  J Virol       Date:  2002-08       Impact factor: 5.103

6.  Human papillomavirus 16-specific T cell responses in classic HPV-related vulvar intra-epithelial neoplasia. Determination of strongly immunogenic regions from E6 and E7 proteins.

Authors:  I Bourgault Villada; M Moyal Barracco; S Berville; M L Bafounta; C Longvert; V Prémel; P Villefroy; E Jullian; T Clerici; B Paniel; B Maillère; J Choppin; J G Guillet
Journal:  Clin Exp Immunol       Date:  2009-07-30       Impact factor: 4.330

7.  Gene expression profiling informs HPV cervical histopathology but not recurrence/relapse after LEEP in ART-suppressed HIV+HPV+ women.

Authors:  Emmanouil Papasavvas; Andrew V Kossenkov; Livio Azzoni; Nicola M Zetola; Agnieszka Mackiewicz; Brian N Ross; Matthew Fair; Surya Vadrevu; Doreen Ramogola-Masire; Ian Sanne; Cynthia Firnhaber; Luis J Montaner
Journal:  Carcinogenesis       Date:  2019-04-29       Impact factor: 4.944

8.  Determinants of incident vulvovaginal candidiasis in human immunodeficiency virus-positive women.

Authors:  E Shifrin; D Matityahu; J Feldman; H Minkoff
Journal:  Infect Dis Obstet Gynecol       Date:  2000

9.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia.

Authors:  J C Steele; C H Mann; S Rookes; T Rollason; D Murphy; M G Freeth; P H Gallimore; S Roberts
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

Review 10.  The Interaction between Human Immunodeficiency Virus and Human Papillomaviruses in Heterosexuals in Africa.

Authors:  Anna-Lise Williamson
Journal:  J Clin Med       Date:  2015-04-02       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.